摘要
目的:研究犀黄丸提取液对MDA-MB-231乳腺癌细胞功能的影响。方法:采用CCK-8法检测犀黄丸提取液对细胞半抑制浓度(IC50)和细胞活力的影响;采用流式细胞技术检测细胞凋亡;transwell法检测细胞转移能力;采用克隆形成实验检测细胞增殖能力。结果:犀黄丸提取液干预细胞72 h的IC50值为15.08 g·L~(-1);以15.08 g·L~(-1)的犀黄丸提取液干预细胞72 h后,相对未加药组,其细胞活力显著下降(P<0.01),早期凋亡和晚期凋亡均显著升高(P<0.01),细胞迁移和增殖能力均显著下降(P<0.01)。结论:本研究从细胞水平上证实了犀黄丸具有显著促进细胞凋亡、抑制细胞增殖、转移和降低细胞活力的能力。
Objective:To study the effect of Xihuang Pill extract solution on the function of MDA-MB-231 Breast cancer cells.Methods:CCK-8 assay was used to detect the semi-inhibitory concentration(IC50) and cell viability of Xihuang Pill extract solution;cell apoptosis was detected with flow cytometry;cell transfer ability was detected with transwell assay;cell proliferation was detected with colony formation assay.Results:The IC50 value of Xihuang Pill extract in intervention of cells for 72 h was 15.08 g·L~(-1).After interfering with cells with 15.08 g·L~(-1) of Rhubarb Pills for 72 h,the cell viability was significant compared with the untreated group.Decreased(P<0.01),early apoptosis and late apoptosis were significantly increased(P<0.01),and cell migration and proliferation ability were significantly decreased(P<0.01).Conclusion:This study demonstrates that Xihuang Pill has a significant ability to promote apoptosis,inhibit cell proliferation,metastasis and cell viability at the cellular level.
引文
[1]SIEGEL R,NAISHADHAM D,JEMAL A.Cancer statistics,2013[J].CA Cancer J Clin,2013,63(1):11-30.
[2]WHO.Cancer:fact sheet number 297[J].February 2012.http://www.who.int/mediacentre/factsheets/fs297/en/index.htmL(accessed Jan 3,2012).
[3]FOROUZANFAR MH,FOREMAN KJ,DELOSSANTOS AM,et al.Breast and cervical cancer in 187 countries between 1980 and 2010:a systematic analysis[J].Lancet,2011,378:1461-1484.
[4]那显臣.犀黄丸加味治疗乳腺癌1例[J].中国中医药信息杂志,1998,5(5):39.
[5]ZHENG W,HAN S,JIANG S,et al.Multiple effects of Xihuang pill aqueous extract on the Hs578T triple-negative breast cancer cell line[J].Biomed Rep.2016,5(5):559-566.
[6]钱树树,李冬云,李潇.中医药治疗乳腺癌淋巴水肿研究进展[J].中国中西医结合杂志,2018,38(8):1019-1022.
[7]邹珊珊,徐榕,何琪杨.复方中药紫龙金克服肿瘤细胞多耐药性的机制[J].中国中西医结合杂志,2010,30(6):601-606.
[8]WANG M,MENG J Y,HE S F.Xihuang Pill Induces Mesenchymal-Epithelial Transition and Inhibits Loss of Apical-Basal Polarity in Colorectal Cancer Cell through Regulating ZEB1-SCRIB Loop[J].Chin J Integr Med,2014,20(10):751-757.
[9]PAN G,WANG W,WANG L,et al.Anti-breast cancer effects and mechanisms of Xihuang pill on human breast cancer cell lines[J].J Tradit Chin Med,2013,33(6):770-778.
[10]HE L J,LI J S,CHEN X,et al.Effect of serum containing Xihuang pill on proliferation of human breast cancer cell line MDA-MB-435 and MCF-7 Cells[J].Zhongguo Zhong Yao Za Zhi,2018,43(13):2784-2788.
[11]王鑫,王艳翚.中药标准化问题与对策研究[J].中华中医药杂志,2018,33(1):22-25.
[12]董玲,孙裕,裴纹萱,等.基于全程质量控制理念的中药标准化体系研究思路探讨[J].中国中药杂志,2017,63(23):4481-4487.
[13]HAO J,JIN Z,ZHU H,et al.Antiestrogenic Activity of the Xi-Huang Formula for Breast Cancer by Targeting the Estrogen Receptor α[J].Cell Physiol Biochem,2018,47(6):2199-2215.
[14]梁文波,张雪梅,送旦旨.西黄丸含药血清对人乳腺癌细胞生长的影响[J].时珍国医国药,2007,18(6):1371-1372.